Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. A Retrospective Real-world Study Of Prognostic Factors Associated With Egfr Mutated Lung Cancer With Leptomeningeal Metastasis.
  1. Home
  3. A Retrospective Real-world Study Of Prognostic Factors Associated With Egfr Mutated Lung Cancer With Leptomeningeal Metastasis.

Related Experiment Video

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal

Yingxi Wu1, Yuhua Zhao1, Yufeng Wu1

  • 1Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China; Institute of Cancer Research, Henan Academy of Innovations in Medical Science, Zhengzhou, China.

Clinical Lung Cancer
|February 28, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

For EGFR-mutated lung cancer with leptomeningeal metastasis (LM), primary LM and brain metastases indicate poorer survival. Combining tyrosine kinase inhibitors (TKI) with antiangiogenic therapy may improve outcomes for these patients.

Keywords:
Anti-angiogenicEGFR mutationNon–small-cell lung cancerOverall survivalTyrosine kinase inhibitors

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Related Experiment Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Area of Science:

  • Oncology
  • Genetics
  • Neurology

Background:

  • Leptomeningeal metastasis (LM) is a severe complication of non-small cell lung cancer (NSCLC).
  • Epidermal growth factor receptor (EGFR) mutations are common drivers in NSCLC, influencing treatment strategies.
  • Understanding prognostic factors in EGFR-mutated NSCLC with LM is crucial for optimizing patient care.

Purpose of the Study:

  • To identify clinical and treatment factors affecting the prognosis of patients with EGFR-mutated lung cancer and LM.
  • To evaluate the impact of specific EGFR mutations (exon 19 deletion vs. exon 21 L858R) on survival.
  • To assess the efficacy of different treatment regimens, including tyrosine kinase inhibitors (TKI) and antiangiogenic therapy, in managing EGFR-mutated NSCLC with LM.

Main Methods:

  • Retrospective analysis of clinical data from 123 patients with advanced EGFR-mutated lung cancer and LM.
  • Data collected from Henan Cancer Hospital between January 2016 and December 2020.
  • Follow-up until September 2021 to analyze median overall survival (mOS) in relation to clinical characteristics and treatments.

    • Main Results:

    • Patients with EGFR exon 19 deletion (19del) showed longer mOS (30.1 months) than those with exon 21 L858R (26.0 months).
    • Primary LM (21.2 months) and combined brain metastases (25.4 months) were associated with significantly shorter mOS compared to secondary LM (28.3 months) and no brain metastases (33.4 months), respectively.
    • Combining EGFR-TKI with antiangiogenic therapy (bevacizumab) delayed LM onset and prolonged survival (mOS1: 19.4 months vs. 13.9 months; mOS2: 14.5 months vs. 10.0 months) compared to EGFR-TKI alone.

    Conclusions:

    • EGFR-TKI combined with antiangiogenic therapy may offer a survival benefit for NSCLC-LM patients with EGFR mutations.
    • Primary LM and concurrent brain metastasis are identified as negative prognostic factors for overall survival.
    • Further research into combination therapies is warranted to improve outcomes for this patient population.